The following documents related to health care concerns of people 50-plus are presented in reverse chronological order.
L: On December 28, 2016 AARP sent letters to the entire Congress expressing AARP’s views on the ACA and health care reform. AARP supports the Patient Protection and Affordable Care Act (ACA) because on balance it addresses health care priorities that are important to all Americans age 50 and older: protecting and improving Medicare’s benefits and financing; providing access to affordable quality coverage; preventing insurers from engaging in discriminatory practices; lowering prescription drug costs; providing new incentives to expand home and community based services; and strengthening efforts to fight fraud, waste, and abuse. As Congress considers legislation to repeal and replace the ACA, it will be important for any health care legislation to include older Americans’ priorities. House (PDF); Senate (PDF)
L: On November 28, 2016 AARP sent a letter to Senators Warren and Grassley endorsing the Over-the-Counter (OTC) Hearing Aid Act of 2016. This bill, by making certain types of hearing aids available over the counter, requiring the FDA to issue regulations on this new category of over-the-counter hearing aids, and requiring the FDA to update its draft guidance on Personal Sound Amplification Products (PSAPs), among other reforms, would help create a more consumer-friendly market for hearing devices. (PDF)
L: On November 29, 2016 AARP sent a letter to Senators Hatch, Wyden, Isakson, and Warner expressing support for the direction of the the Creating High-Quality Results and Outcomes Necessary to Improve Chronic (CHRONIC) Care Act. AARP is generally supportive of the direction of your draft legislation, and believe that it would take some important steps to improve care for the millions of Medicare beneficiaries with chronic conditions. (PDF)
L: On October 26, 2016, AARP along with the AFL-CIO, OXFAM America, Consumers Union, and Doctors Without Borders sent a letter to President Obama concerning the Trans-Pacific Partnership (TPP). The letter collectively expressed concern about recent reports that the Administration is working behind the scenes to craft TPP implementing legislation and possibly enter into side letters that would mean even more lengthy monopoly protections for biologics than the already onerous provisions in the TPP agreement. (PDF)